MERCK KGAA

The Monoclonal Antibodies Reagents Market is projected to grow at a CAGR of 10.23%, reaching USD 153.23 Billion by 2032, driven by advancements in biomedical research, clinical diagnostics, and therapeutic applications. Key market drivers include the rise in targeted therapies, biopharmaceutical R&D, expanding diagnostic applications, increasing prevalence of chronic diseases, and growth in point-of-care testing. The market is segmented by type, application, and end-user, with North America leading, followed by Europe and the Asia-Pacific region. Major players include Thermo Fisher Scientific, Merck KGaA, Abcam PLC, Bio-Rad Laboratories, and GenScript Biotech Corporation.

Vaccinex to present pepinemab efficacy and safety data at CTAD Conference, hypothesizing pepinemab's ability to block SEMA4D signaling and slow Alzheimer's progression, with focus on cognitive decline and biomarkers. Pepinemab also shown to preserve brain vasculature integrity.

The global Rx-to-OTC switches market is projected to reach USD 66.5 billion by 2033, driven by consumer convenience, cost-effectiveness, and regulatory support.

The Global Organoid Market is projected to reach $15.01 billion by 2031, driven by tumor modeling, biobanking, and personalized drugs. Organoids, 3D structures from stem cells, mimic in vivo organs, aiding cancer research and drug discovery. North America leads in market share, with Asia Pacific expected to grow the fastest. Key players include STEMCELL Technologies, Hubrecht Organoid Technology, and Thermo Fisher Scientific.

Astellas Pharma's zolbetuximab, branded Vyloy, receives FDA approval for first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing CLDN18.2, offering a new targeted therapy for HER2-negative cases. Vyloy, acquired from Ganymede Pharmaceuticals, demonstrated significant improvements in progression-free and overall survival in Phase 3 trials, with common side effects including nausea, vomiting, and decreased appetite.

Germany IVD raw materials market valued at USD 989.1 million in 2024, projected to reach USD 2,658.9 million by 2033, growing at a CAGR of 11.7%. Driven by chronic disease prevalence, government healthcare investments, and diagnostic tech advancements. High regulatory standards and compliance costs are restraining factors. Personalized medicine adoption offers significant market opportunities.

The North America Cell and Gene Therapy Manufacturing QC Market is projected to grow from USD 1,081.20 million in 2025 to USD 6,569.31 million by 2033, at a CAGR of 25.3%. Key drivers include increasing clinical trials and investments, rising therapy approvals, and advanced biopharmaceutical companies. High QC infrastructure costs are a restraint, while expansion of contract QC services offers opportunities.

The Immunohistochemistry Market is projected to grow from USD 3.1 billion in 2023 to USD 5.5 billion by 2031, at a CAGR of 7.4%. Factors driving growth include automation, advanced IHC solutions, and increased demand for personalized medicine. Multiplexed IHC, enabling detailed analysis from a single sample, is a key emerging technology. North America leads in market share due to biotech advancements and high cancer prevalence.

The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences Inc.

Astellas secures FDA approval for Vyloy, its first-in-class CLDN18.2-targeting cancer therapy, for certain gastric cancers. Vyloy, already approved in Japan, EU, and GB, demonstrated reduced risk of disease progression or death in SPOTLIGHT and GLOW trials. The FDA also cleared a CLDN18.2 diagnostic test from Roche for patient eligibility.